Ovid Therapeutics is a biopharmaceutical company developing targeted small-molecule medicines for epilepsies and other brain conditions linked to excess neural excitability. Its pipeline includes candidates such as a next-generation GABA-aminotransferase inhibitor for treatment-resistant seizures and an oral KCC2 activator for central nervous system disorders. The company focuses on mechanisms that aim to reduce seizures while improving safety and tolerability for patients and families affected by neurological disease.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 6.3 | — | -4.7 | — |
| Q3 2025 | 0.1 | — | -12.2 | — |
| Q4 2025 | 0.7 | — | 9.7 | — |
| Q1 2026 | 0 | — | -17 | — |
| Q2 2026 | 0.7 | -88.3% | -15 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: YD Bio Ltd (YDES), AMC Global Media Inc. (AMCX), Churchill Capital Corp XIII (XIII), Oportun Financial Corporation (OPRT), Nathan's Famous, Inc. (NATH), Cogent Communications Holdings, Inc. (CCOI)